key: cord-0336045-1iago9rr
authors: Kojima, N.; Shrestha, N.; Klausner, J. D.
title: A Systematic Review of the Protective Effect of Prior SARS-CoV-2 Infection on Repeat Infection
date: 2021-08-29
journal: nan
DOI: 10.1101/2021.08.27.21262741
sha: 8e6f2745bff96dcac4a6921f88b98a745560cade
doc_id: 336045
cord_uid: 1iago9rr

Introduction: We systematically reviewed studies to estimate the risk of SARS-CoV-2 reinfection among those previously infected with SARS-CoV-2. Methods: For this systematic review, we searched scientific publications on PubMed and, the pre-print server, MedRxiv through August 18, 2021. Eligible studies were retrieved on August 18, 2021. We used the following search term on PubMed: (((Cohort Studies [Majr]) AND (COVID-19 [Mesh] OR SARS-CoV-2 [Mesh])) OR Reinfection [Majr]) OR Reinfection [Mesh]. We used the following search term on MedRxiv: Cohort Studies AND COVID-19 OR SARS-CoV-2 AND Reinfection. The search terms were broad to encompass all possibilities for applicable studies. There were no restrictions on the date of publication. Studies that did not describe cohorts with estimates of the risk of SARS-CoV-2 reinfection among those with previous infection were excluded. Studies that included vaccinated participants were either excluded or limited to sub-groups of non-vaccinated individuals. To identify relevant studies with appropriate control groups, we developed the following criteria for studies to be included in the systematic analysis: (1) baseline polymerase chain reaction (PCR) testing, (2) a negative comparison group, (3) longitudinal follow-up, (4) a cohort of human participants, i.e., not a case report or case series, and (5) outcome determined by PCR. The review was conducted following PRISMA guidelines. We assessed for selection, information, and analysis bias, per PRISMA guidelines. Results: We identified 1,392 reports. Of those, 10 studies were eligible for our systematic review. The weighted average risk reduction against reinfection was 90.4% with a standard deviation of 7.7%. Protection against SARS-CoV-2 reinfection was observed for up to 10 months. Studies had potential information, selection, and analysis biases. Conclusions: The protective effect of prior SARS-CoV-2 infection on re-infection is high and similar to the protective effect of vaccination. More research is needed to characterize the duration of protection and the impact of different SARS-CoV-2 variants.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent 55 of coronavirus disease 2019 , is highly infectious and continues to cause 56 substantial morbidity and mortality (Dong et al., 2020; Jin et al., 2020) . Prior to the 57 development of highly safe and effective vaccines for SARS-CoV-2 infection, scientists 58

reported that a history of COVID-19 was associated with reduced risk of SARS-CoV-2 59 reinfection (Addetia et al., 2020). Virus-induced immunity has been described in many 60 infections and is responsible for the decline of epidemic spread associated with 61 exhaustion of the susceptible population (Rouse & Sehrawat, 2010) . However, the 62 duration and degree of the protective effect of SARS-CoV-2s-induced immunity is poorly 63 studied. 64

Prior epidemiologic studies have found that individuals who are SARS-CoV-2 antibody-66 positive are protected against reinfection (Abu-Raddad et al., 2021; Harvey et al., 2021; 67 Jeffery-Smith et al., 2021) . Furthermore, investigators have reported that even those 68 with prior SARS-CoV-2 infection who lacked detectable antibodies were at 80% lower 69 risk of reinfection than people who were SARS-CoV-2 naïve (Breathnach et al., 2021) . 70

One retrospective study that analyzed test results among nearly 10,000 individuals with 71 prior SARS-CoV-2 infection found that only 0.7% became reinfected with SARS-CoV-2 72 (Qureshi et al., 2021) . 73 74 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 29, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Final Version 5 Other studies have also described reduced risk of infection, morbidity, and mortality 75 among those with prior COVID-19. A study conducted in Austria found that the 76 frequency of hospitalization and death due to a SARS-CoV-2 reinfection was 5 out of 77 14,840 (0.03%) and 1 out of 14,840 (0.01%), respectively (Pilz et al., 2021) . CoV-2 reinfection among those with prior infection was similar in magnitude to the 85 relative risk reduction against SARS-CoV-2 infection among those who were vaccinated 86 (Thompson et al., 2021) . In a longitudinal study conducted among employees at the 87 Cleveland Clinic, vaccination was not found to be associated with a lower risk of SARS-88

CoV-2 infection among people with prior COVID-19 (Shrestha et al., 2021) . 89 90 Despite the availability of safe and effective vaccines, rates of SARS-CoV-2 infection 91 are again increasing, especially among those without immunity (Christie et al., 2021) . 92

We aimed to determine the protective effect of previous infection among those who 93

have not been also vaccinated against SARS-CoV-2. We systematically reviewed 94 published longitudinal studies to estimate the risk of SARS-CoV-2 reinfection among 95 those previously infected with SARS-CoV-2. 96 97 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) For this systematic review, we searched scientific publications on PubMed and the pre-99 print server, MedRxiv. through August 18, 2021. Eligible studies were retrieved on 100

August 18, 2021. We used the following search term on PubMed: ((("Cohort 101

Studies"[Majr]) AND ( "COVID-19" [Mesh] OR "SARS-CoV-2"[Mesh] )) OR 102 "Reinfection"[Majr]) OR "Reinfection" [Mesh] . We used the following search term on 103 MedRxiv: "Cohort Studies" AND "COVID-19" OR "SARS-CoV-2" AND "Reinfection". 104

The search terms were broad to encompass all possibilities for applicable studies. 105

There were no restrictions on the date of publication. Studies that did not describe 106 cohorts with estimates of the risk of SARS-CoV-2 reinfection among those with previous 107 infection were excluded. Studies that included vaccinated participants were either 108 excluded or limited to sub-groups of non-vaccinated individuals. 109

To identify relevant studies with appropriate control groups, we developed the following 111 criteria for studies to be included in the systematic analysis: (1) baseline polymerase 112 chain reaction (PCR) testing, (2) a negative comparison group, (3) longitudinal follow-up, 113

(4) a cohort of human participants, i.e., not a case report or case series, and (5) 114 outcome determined by PCR. 115

The review was conducted following PRISMA guidelines (Page et al., 2021). Two 117 reviewers identified studies for the review. One reviewer collected data from each report 118 and the other reviewer independently checked the work. Abstracts were reviewed and 119

ineligible studies were not included. We reviewed selected reports to extract the 120 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 29, 2021. ; https://doi.org/10.1101/2021.08.27.21262741 doi: medRxiv preprint Final Version 7 following information: Author, year of publication, study cohort, reinfection risk, and 121 follow-up time in person-years, when available. We assessed for selection, information, 122 and analysis bias, per PRISMA guidelines. Due to the heterogeneity of the studies 123 reviewed, sensitivity analyses and a meta-analysis was not attempted. Studies with 124 outcomes were listed in a table. 125

There was no funding for this study. 127 128

We identified 1,392 reports ( Figure) . Of those reports, 10 studies met the above criteria 130 from 6 different countries. The total population in the 10 studies included 9,930,470 131 individuals with a median observation period that ranged from one to 10.3 months. 132

We found that the relative decreased risk of SARS-CoV-2 reinfection ranged between 134 80.5 to 100% compared to those without prior infection (Table) . The weighted average 135 risk reduction against reinfection was 90.4%, with a standard deviation of 7.7%. their study 51 participants withdrew and 4,913 participants were excluded because they 143 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 29, 2021. relatively healthier people, and since the study was done entirely after vaccines became 152 available, there was also likely selection bias due to differential participation among 153 those who decided not to get vaccinated (Shrestha et al., 2021) . with PCR confirmed initial and repeat infections. We found that the weighted average 165 risk reduction against reinfection was 90.4%. Protection was observed up to 10 months. 166 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

repeat SARS-CoV-2 infection, although the absolute increased risk of re-infection was 189 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 29, 2021. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 29, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Final Version 11 However a recent pre-print from a study conducted in the United Kingdom found among 212 persons infected during a period of nearly exclusive Delta SARS-CoV-2 transmission, 213 those fully vaccinated with BNT162b2 and ChAd0x1 (had similar levels of protection 214 (82% and 67%, respectively) as those with previous infection (73%) (Pouwels; et al., 215 2021) . Additionally, in a recent retrospective cohort study that was conducted in Israel 216 which compared rates of SARS-CoV-2 infection or reinfection with the Delta variant 217 among SARS-CoV-2-naïve individuals who received the BNT162b2 vaccine to people 218 who had recovered from COVID-19, found that vaccinated, but SARS-CoV-2-naïve 219 people, had an increased risk of infection with the Delta variant when compared to 220 people who had recovered from COVID-19 (Gazit et al., 2021) . This association was 221 statistically significant in two models that either matched to the time of the first event 222

(13.1-fold increased risk) or did not match to time of first event (6.0-fold increased risk). . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 29, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Final Version 12 There is consistent epidemiologic evidence that prior SARS-CoV-2 infection provides 234 substantial immunity to repeat SARS-CoV-2 infection. Prior SARS-CoV-2 infections 235 provide similar protection when compared to vaccination for SARS-CoV-2. Longer 236 follow-up studies are needed to determine how long protection lasts for natural immunity, . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 29, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 protects against reinfection for at least seven months with 95% efficacy. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 29, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 

SARS-CoV-2 antibody-positivity

infection is similar to that of BNT162b2 vaccine protection: A three-month 299 nationwide experience from Israel. medRxiv. 300Hall, V. J., Foulkes, S., Charlett, A., Atti, A., Monk, E. J. M., Simmons, R., Wellington, 301 E., Cole, M. J., Saei, A., Oguti, B., Munro, K., Wallace, S., Kirwan, P. D., Shrotri, 302 M., Vusirikala, A., Rokadiya, S., Kall, M., Zambon, M., Ramsay, M., Brooks, T., 303 Brown, C. S., Chand, M. A., Hopkins, S., & Group, S. S. (2021) . SARS-CoV-2 304 infection rates of antibody-positive compared with antibody-negative health-care 305 workers in England: a large, multicentre, prospective cohort study (SIREN) . Jeffery-Smith, A., Iyanger, N., Williams, S. V., Chow, J. Y., Aiano, F., Hoschler, K., 319Lackenby, A., Ellis, J., Platt, S., Miah, S., Brown, K., Amirthalingam, G., Patel, 320 M., Ramsay, M. E., Gopal, R., Charlett, A., Ladhani, S. N., & Zambon, M. (2021) . 321 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted August 29, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Final Version 16 Antibodies to SARS-CoV-2 protect against re-infection during outbreaks in care 322 homes, September and October 2020. Euro Surveill, 26(5) . . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 29, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Final Version 1 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted August 29, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021